First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 156-166

  Pietrantonio, Filippo ^a   Cremolini, Chiara ^b   Petrelli, Fausto ^c   Di Bartolomeo, Maria ^a   Loupakis, Fotios ^b   Maggi, Claudia ^a   Antoniotti, Carlotta ^b   de Braud, Filippo ^a   Falcone, Alfredo ^b   Iacovelli, Roberto ^a,d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Overall survival; Panitumumab; Randomized clinical trials

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN;

CANCER CHEMOTHERAPY; CANCER MORTALITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; METASTATIC COLORECTAL CANCER; ONCOGENE RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; WILD TYPE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; MORTALITY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BEVACIZUMAB; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942198699     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.016     Document Type: Review

References (47)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Peeters M., Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum: applying current evidence to clinical practice. Cancer Treat Rev 2012, 38:397-406.
3. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
4. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
5. Bokemeyer C., Van Cutsem E., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012, 48:1466-1475.
6. Loupakis F., Cremolini C., Salvatore L., et al. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 2012, 118:1523-1532.
7. Ince W.L., Jubb A.M., Holden S.N., et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989.
8. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
9. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
10. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20:84-90.
11. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
12. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-1034.
13. Schwartzberg L.S., Rivera F., Karthaus M., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014, 32:2240-2247.
14. Heinemann V., von Weikersthal L.F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:1065-1075.
15. Seymour M.T., Brown S.R., Middleton G., et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013, 14:749-759.
16. Peeters M., Oliner K.S., Parker A., et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013, 19:1902-1912.
17. Ciardiello F., Lenz H.J., Kohne C.H., et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014, 32(5s). (suppl; abstr 3506).
18. Peeters M., Oliner K.S., Price T.J., et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014, 32(5s). (suppl; abstr LBA387).
19. The summary for product characteristics for cetuximab available at: 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_med_000769.jsp&mid=WC0b01ac058001d124〉.
20. The summary for product characteristics for panitumumab available at: 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000741/human_med_001128.jsp&mid=WC0b01ac058001d124〉.
21. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
22. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. PRISMA Group.
23. Morris J.A., Gardner M.J. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988, 296:313-1316.
24. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
25. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
26. Review Manager (RevMan) [Computer program]. Version 5.2 2012, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Available at: 〈http://ims.cochrane.org/revman/download〉.
27. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
28. Bokemeyer C., Kohne C.H., Ciardiello F., et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 2014, 32(5s). (suppl; abstr 3505).
29. Lenz H., Niedzwiecki D., Innocenti F., et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Ann Oncol 2014, 25(4s). (suppl; abstr 501O).
30. Stintzing F., Modest D.P., Fischer von Weikersthal L., et al. Independent radiological evaluation of objective response rate, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. Ann Oncol 2014, 25(4s). (suppl; abstr LBA11).
31. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
32. Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
33. Petrelli F., Borgonovo K., Cabiddu M., et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012, 13:107-114.
34. Mok T., Kim D.W., Wu Y.L., et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014, 32(5s). (suppl; abstr 8002).
35. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
36. Sorich M.J., Wiese M.D., Rowland A., et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015, 26:13-21.
37. Adams R.A., Meade A.M., Madi A., et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 2009, 100:251-258.
38. Vale C.L., Tierney J.F., Fisher D., et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer?. A systematic review and meta-analysis. Cancer Treat Rev 2012, 38:618-625.
39. Van Cutsem E., Cervantes A., Nordlinger B., et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(3s suppl.).
40. Cunningham D., Lang I., Marcuello E., et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 14:1077-1085.
41. Loupakis F., Cremolini C., Masi G., et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014, 371:1609-1618.
42. Baas J.M., Krens L.L., Guchelaar H.J., et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev 2012, 38:505-514.
43. Buyse M., Thirion P., Carlson R.W., et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis-Meta-Analysis Group in Cancer. Lancet 2000, 356:373-378.
44. Mao C., Yang Z.Y., Hu X.F., et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012, 23:1518-1525.
45. Bardelli A., Corso S., Bertotti A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013, 3:658-673.
46. Bertotti A., Migliardi G., Galimi F., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011, 1:508-523.
47. Pietrantonio F., Maggi C., Di Bartolomeo M., et al. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS ONE 2014, 9:e92147.